Alkeon Capital Management’s BioCryst Pharmaceuticals BCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $51.2M | Sell |
5,714,021
-1,500,000
| -21% | -$13.4M | 0.09% | 58 |
|
|
2025
Q1 | $54.1M | Buy |
7,214,021
+120,199
| +2% | +$901K | 0.11% | 52 |
|
|
2024
Q4 | $53.3M | Hold |
7,093,822
| – | – | 0.11% | 50 |
|
|
2024
Q3 | $53.9M | Sell |
7,093,822
-5,662
| -0.1% | -$43K | 0.09% | 55 |
|
|
2024
Q2 | $43.9M | Buy |
7,099,484
+3,000,000
| +73% | +$18.5M | 0.07% | 58 |
|
|
2024
Q1 | $20.8M | Buy |
4,099,484
+2,430,000
| +146% | +$12.3M | 0.04% | 62 |
|
|
2023
Q4 | $10M | Sell |
1,669,484
-2,829
| -0.2% | -$16.9K | 0.02% | 68 |
|
|
2023
Q3 | $11.8M | Hold |
1,672,313
| – | – | 0.02% | 72 |
|
|
2023
Q2 | $11.8M | Buy |
1,672,313
+403,461
| +32% | +$2.84M | 0.02% | 80 |
|
|
2023
Q1 | $10.6M | Sell |
1,268,852
-216,965
| -15% | -$1.81M | 0.02% | 83 |
|
|
2022
Q4 | $17.1M | Buy |
1,485,817
+20,532
| +1% | +$236K | 0.07% | 84 |
|
|
2022
Q3 | $18.5M | Buy |
1,465,285
+296,940
| +25% | +$3.74M | 0.06% | 87 |
|
|
2022
Q2 | $12.4M | Sell |
1,168,345
-19,500
| -2% | -$206K | 0.03% | 91 |
|
|
2022
Q1 | $19.3M | Buy |
+1,187,845
| New | +$19.3M | 0.04% | 94 |
|